Condition: MTAP-deleted Solid Tumors · Sponsor: Bayer
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses. Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse. The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose e…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital | Birmingham, Alabama, United States | Not Yet Recruiting |
| City of Hope - Duarte Cancer Center | Duarte, California, United States | Not Yet Recruiting |
| UCLA Health Bowyer Oncology Center | Los Angeles, California, United States | Not Yet Recruiting |
| UCSF Helen Diller Medical Center at Parnassus Heights - Neurology | San Francisco, California, United States | Not Yet Recruiting |
| Stanford University Medical Center - Neurology | Stanford, California, United States | Not Yet Recruiting |
| UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center | Aurora, Colorado, United States | Not Yet Recruiting |
| Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's | Denver, Colorado, United States | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona | Orlando, Florida, United States | Recruiting |
| Massachusetts General Hospital - Neurology | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute - Oncology Department | Boston, Massachusetts, United States | Not Yet Recruiting |
| START | Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai - Oncology | New York, New York, United States | Not Yet Recruiting |
+ 48 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06914128